Investor Presentaiton
JLL - Q3'FY20 Financial Highlights
Particulars¹
Revenue
Pharmaceuticals²
Q3'FY19 Q3'FY20
YOY
Change (%)
■
Revenue at Rs 2,315 Crore, a decrease of 3% YoY and an increase of 2% QoQ
Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY, contributing 63%
to revenue
•
LSI revenue at Rs 797 Crore decreased by 11% YoY and increased by 6% QoQ
Drug Discovery & Development Solutions (DDDS) ³ revenue was at Rs 68 Crore, an
increase of 26% YoY and 12% QoQ
Reported EBITDA at Rs 513 Crore decreased 2% YoY but increased 7% sequentially. EBITDA
margin at 22.2% vs. 22% in Q3'FY19 and 21.2% in Q2'FY20
1,424
1,450
Life Science Ingredients
899
797
Drug Discovery & Development Solutions³
54
Total Revenue from Operations
2,377
68
2,315
2%
(11%)
26%
(3%)
•
EBITDA
Pharmaceuticals²
388
411
6%
Life Science Ingredients
126
100
(21%)
Drug Discovery & Development Solutions
5
17
270%
Unallocated Corporate Expenses
4
(15)
Reported EBITDA
522
513
(2%)
Adjusted EBITDA
518
516
(0%)
15
35
261
203
(22%)
16.7
12.8
(24%)
EBITDA Margins
Pharmaceuticals
27.2%
28.4%
Life Science Ingredients
14.0%
12.6%
Drug Discovery & Development Solutions
8.6%
25.4%
Reported EBITDA
22.0%
22.2%
Adjusted EBITDA
21.8%
22.3%
Exceptional Items
PAT
EPS
Geography Wise Revenue¹
636
517
1,240 1,296
Pharmaceuticals EBITDA at Rs 411 Crore an increase of 6% YoY with a margin of
28.4% as compared to 27.2% in Q3'FY19
LSI EBITDA at Rs 100 Crore decreased by 21% YoY and increased by 10% QoQ;
Q3'FY20 margin at 12.6% as compared to 14% in Q3'FY19 and 12.1% in Q2'FY20
DDDS EBITDA at Rs 17 Crore increased from Rs 5 Crore in Q3'FY19; Q3'FY20 margin at
25.4% an increase from 8.6% in Q3'FY19
○ Drug Discovery Services EBITDA was at Rs 21 Crore up from Rs 5 Crore in Q3'FY19
with margins of 31.1%
In Q3'FY19 there was a forex gain of Rs 25 Crore on account of restatement of
deposits vs. nil in this quarter
■ Adjusted EBITDA after one-off expenses at Rs 516 Crore vs. Rs 518 Crore in Q3'FY19.
Adjusted EBITDA margin for the quarter is 22.3% vs. 21.8% in Q3'FY19
☐
Finance costs at Rs 72 Crore vs. Rs 53 Crore in Q3'FY19 and Rs 72 Crore in Q2'FY20
Exceptional charge of Rs 23 Crore related to prepayment of high yield bonds and NCDs and
Rs 11 Crore related to write-off of fixed assets not in use. Q3'FY19 charge of 15 Crore is
related to IFC Stock settlement charge
329 297
173 206
◉
Net Profit at Rs 203 Crore down 22% YoY and 18% QoQ. EPS of Rs 12.8 vs. Rs 16.7 in
Q3'FY19
Capex in Q3'FY20 of Rs 111 Crore
India
North
America
■Q3'FY19
Europe &
Japan
ROW
■Q3'FY20
1. All figures are in Rs Crore unless otherwise stated
2.
Pharmaceuticals segment includes India Branded Pharmaceuticals business under the Generics segment
3. Drug Discovery & Development Solutions include the Drug Discovery Services (Jubilant Biosys & Jubilant Chemsys) business and Proprietary Drug Discovery business (Jubilant BILANT
Therapeutics)
LIFESCIENCESView entire presentation